trial update, page-2

re: trial update market likes it! Sydney 25 January 2005: Ventracor Limited (ASX: VCR) today provided a summary of a recent
presentation to the international medical community on the results of the Pilot Trial by chief
medical investigator Professor Don Esmore.
Speaking at the recent Second Asian Pacific Congress of Heart Failure in Singapore, Professor
Esmore said clinical results from the VentrAssist™ pilot trial last year were “very encouraging.”
“It is my opinion the VentrAssist™ left ventricular assist system (LVAS) has proven efficacious
and reliable. No other device has ever been trialled in such a difficult patient population.
“We were very pleased with the clinical data that shows an improved quality of life for very sick
and elderly patients,” Professor Esmore said adding data collected to date indicated:
- non-pulsatile flow in the elderly reversed pre-implant end organ dysfunction
- contemporary medium term results showed satisfactory neurocognitive function and
improved quality of life
- an acceptable serious adverse event profile validates the definitive pump design and
deployment.
“At The Alfred we have seen negligible haemolysis, minimal infections, functional improvement in
patients and an improved quality of life.
“The acceptable serious adverse event profile observed clearly validates the pump design and
use in the wider global trial now underway,” Professor Esmore told the audience.
A pilot trial of the VentrAssist™ in nine patients was closed last year and Ventracor is now
conducting a global pivotal trial aimed at obtaining CE marking approval for sale in Europe.
The company has submitted an application to the FDA to begin a clinical trial in the USA this
year.
About Ventracor
Ventracor (ASX:VCR) is an international medical technology company that has developed a life-saving heart
pump, the VentrAssist™ left ventricular assist system (LVAS), for patients in cardiac failure. The company is
focused on commercialising the VentrAssist™ and bringing it to global markets in record time. Ventracor is
confident of obtaining a significant share of the LVAS market, which independent analysts expect to be
valued at between $US7.5 billion and $US12 billion per year.
For a copy of the presentation visit www.ventracor.com. For more information, please contact:
Andrew Geddes
Manager, Investor Relations
Ventracor Limited
(02) 9406 3086
Ventracor Limited 126 Greville Street Chatswood NSW 2067 Australia
T +61 2 9406 3100 F +61 2 9406 3101 W www.ventracor.com
ABN 46 003 180 372